Closely-held ORIC Pharmaceuticals appointed Lori Friedman as CSO, responsible for leading ORIC’s research and preclinical development efforts.
“Lori has a multi-decade record of leadership in oncology drug discovery and translation, including identifying and advancing multiple novel programs into the clinic that eventually achieved regulatory approval and commercialization,” Dr. Jacob Chacko, ORIC CEO, said in a statement.
Ms. Friedman has more than 20 years of experience in cancer research. During her 15-year career at Genentech, she was most recently head of translational oncology for research and early development, where her team advanced more than 20 programs into clinical development. She is also an inventor on 24 issued patents and author on 88 peer-reviewed publications.
Ms. Friedman said she aims to advance the company’s lead program, ORIC-101, and grow ORIC’s pipeline, which targets cancer’s mechanisms of therapeutic resistance.
